RT Journal Article
SR Electronic
T1 Persistent SARS-CoV-2 replication in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.10.20127837
DO 10.1101/2020.06.10.20127837
A1 Folgueira, María Dolores
A1 Luczkowiak, Joanna
A1 Lasala, Fátima
A1 Pérez-Rivilla, Alfredo
A1 Delgado, Rafael
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.10.20127837.abstract
AB Background The diagnosis of SARS-CoV-2 infection is based on viral RNA detection by real-time RT-PCR (rRT-PCR) in respiratory samples. This detection can remain positive for weeks without implying virus viability.Methods We have performed cell culture to assess viral replication in 106 respiratory samples rRT-PCR positive for SARS-CoV-2 from 105 patients with COVID-19. Fifty were samples from 50 patients with mild forms of COVID-19 who did not require hospital admission. Fifty-six samples were obtained from 55 hospitalized patients with severe pneumonia. Samples were obtained at different time points covering the time from clinical diagnosis to the follow up during hospital care.Results In 49 samples (49/106, 46.2%) a cytopathic effect (CPE) was detected in cell culture. Our study demonstrates that while in patients with mild COVID-19, viral viability is maintained in fact up to 10 days in patients with severe COVID-19 the virus can remain viable for up to 32 days after the onset of symptoms. Patients with severe COVID-19 as compared with mild cases, presented infective virus in a significantly higher proportion in samples with moderate or low viral load (Ct value > 26): 22/46 (47.8%) versus 7/38 (18.4%), (p <0.01), respectively.Conclusions Persistent SARS-CoV-2 replication could be demonstrated in severe COVID-19 cases for periods up to 32 days after the onset of symptoms and even at high Ct values. COVID-19 severity is a more determining factor for viral viability than the time elapsed since the onset of symptoms or the Ct value obtained in the RT-PCR assay.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants to RD by the Instituto de Investigacion Carlos III (grants FIS PI 1801007, by the European Union Commission Horizon 2020 Framework Programme: Project VIRUSCAN FETPROACT-2016: 731868. And by Fundacion Caixa-Health Research (Project StopEbola) and to MDF by the Instituto de Investigacion Carlos III (FIS PI1800740).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB of Hospital Universitario 12 de Octubre (Reference 20-232)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon reasonable request